New findings have revealed interactions between combining PD-1/PD-L1 inhibitors with other immune checkpoint inhibitors, angiogenesis inhibitors or chemotherapies, encouraging the immune response and hindering the escape of tumor cells (Antonia et al., 2018). Here, CD274 is linked to neoplasm.